Biomimetic Nanocarriers of Pro‐Resolving Lipid Mediators for Resolution of Inflammation in Atherosclerosis

Abstract

AbstractAtherosclerosis (ATH) is a systemic disease characterized by a chronic inflammatory process and lipid deposition in the arterial walls. The chronic inflammation within ATH lesions results, at least in part, from the failed resolution of inflammation. This process is controlled actively by specialized pro‐resolving lipid mediators (SPMs), namely lipoxins, resolvins, protectins, and maresins. Herein, biomimetic nanocarriers are produced comprising a cocktail of SPMs‐loaded lipid nanoemulsions (LN) covered with macrophage membranes (Bio‐LN/SPMs). Bio‐LN/SPMs retain on their surface the macrophage receptors involved in cellular interactions and the “marker of self” CD47, which impede their recognition and uptake by other macrophages. The binding of Bio‐LN/SPMs to the surface of endothelial cells (EC) and smooth muscle cells (SMC) is facilitated by the receptors on the macrophage membranes and partly by SPMs receptors. In addition, Bio‐LN/SPMs prove functional by reducing monocyte adhesion and transmigration to/through activated EC and by stimulating macrophage phagocytic activity. After intravenous administration, Bio‐LN/SPMs accumulate in the aorta of ApoE‐deficient mice at the level of atherosclerotic lesions. Also, the safety assessment testing reveals no side effects or immunotoxicity of Bio‐LN/SPMs. Thus, the newly developed Bio‐LN/SPMs represent a reliable targeted nanomedicine for the resolution of inflammation in atherosclerosis.